Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01717248 · ClinicalTrials.gov registry record · Phase 1

Safety Study of GCS-100 to Treat Chronic Kidney Disease

A Phase 1 study, sponsored by La Jolla Pharmaceutical Company.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target

NCT01717248: Completed Phase 1 study, sponsored by La Jolla Pharmaceutical Company.

NCT01717248 is a Phase 1 study that has completed, run by La Jolla Pharmaceutical Company. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01717248, a Phase 1 study, has completed, sponsored by La Jolla Pharmaceutical Company.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

Primary Outcome

Assess overall safety of rising dose of GCS-100 in CKD patients

Interventions

  • DRUG GCS-100

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2013-01
Est. Completion 2013-06
Phase Phase 1
La Jolla Pharmaceutical Company

12 total trials

What the finished NCT01717248 record still lists

NCT01717248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).

The record links to 0 conditions, and to 1 intervention - of which GCS-100 is the first listed.

NCT01717248 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01717248 about?

NCT01717248 is a clinical study titled "Safety Study of GCS-100 to Treat Chronic Kidney Disease". The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

What is the current status of trial NCT01717248?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-01. Estimated completion is 2013-06.

What interventions are being tested in trial NCT01717248?

The interventions under investigation include: GCS-100 (DRUG).

Who is sponsoring clinical trial NCT01717248?

This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01717248's enrollment target sits among peer trials

29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01717248, the US trial registry maintained by the National Library of Medicine. NCT01717248 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.